Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000078304 | SCV000110144 | pathogenic | not provided | 2013-03-14 | criteria provided, single submitter | clinical testing | |
3billion | RCV002250557 | SCV002521887 | pathogenic | Fabry disease | 2022-05-22 | criteria provided, single submitter | clinical testing | The variant is not observed in the gnomAD v2.1.1 dataset. Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID:28798024). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.77; 3Cnet: 0.98). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000092572). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. |